JANX — Janux Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.04bn
- $72.08m
- $10.00m
U.S. STOCKS ON THE MOVE-Citi Trends, PG&E, BlackRock
U.S. STOCKS ON THE MOVE-Zscaler, Credo Technology, FedEx
Janux soars as early data of cancer drug exceeds expectations
Brief: Janux Announces Doses Selected For Phase 1B Expansion Trials
Brief: Janux Therapeutics Q3 Basic EPS USD -0.51
Janux Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Janux Therapeutics Q2 Basic EPS USD -0.11
Brief: Janux Therapeutics Names Ronald Barrett As Chairperson
Janux Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Janux Therapeutics Q1 Basic EPS USD -0.3
U.S. RESEARCH ROUNDUP-Caterpillar, Goldman Sachs, Netflix
Janux climbs after report of takeover interest
Media: Cancer-drug maker Janux Therapeutics weighs possible sale - Bloomberg News
U.S. RESEARCH ROUNDUP-Adobe, Microsoft, ServiceNow
U.S. RESEARCH ROUNDUP-Adobe, Microsoft, ServiceNow
Janux Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Janux Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Business Highlights
Brief: Janux Therapeutics Q4 Basic EPS USD -0.25
Janux Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview